Overview
- Jieti Medical raised about 500 million yuan in strategic financing led by Alibaba, with Tencent and other existing investors participating, according to 36Kr.
- The company reports an early‑2026 clinical implant using its own surgical robot and says brain‑controlled interaction was validated in the procedure.
- Jieti plans to run multicenter registration trials this year, targeting enrollment and implantation for roughly 40 patients.
- Its second‑generation WRS02 platform, introduced in December 2025, increases electrode count to 256 and aims to extend applications from motor control to language restoration.
- China’s 2025 pricing guidance from the National Healthcare Security Administration designates several BCI services as separate billable items, while public discourse is intensifying as Neuralink co‑founder Max Hodak touts AI‑BCI human enhancement and makes bold timeline predictions.